Physician profile
Leonid A Tolstunov
NPI 1255487179
$15,152.37
in general payments reported to CMS, 2019-2025
5 companies · $688 in 2025
The $688 reported for 2025 was more than what 87% of Oral and Maxillofacial Pathology providers received nationally (typical 2025 total: $90.97).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,593 · 2020: $500 · 2021: $2,562 · 2022: $1,725 · 2023: $750 · 2024: $1,334 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072 · Education: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.37 |
| Education | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geistlich Pharma, North America, INC. | $11,741.65 | 2019-2025 | Geistlich Bio-Gide, Biomaterials, Bio-Gide |
| Straumann USA LLC | $1,739.38 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $1,526.85 | 2019-2021 | |
| Zimvie INC. | $94.12 | 2024 | |
| Implant Direct Sybron International LLC | $50.37 | 2023 | Biomaterials |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Tolstunov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.